Allianz Asset Management GmbH Sells 18,103 Shares of Docusign Inc. $DOCU

Allianz Asset Management GmbH lessened its position in Docusign Inc. (NASDAQ:DOCU - Free Report) by 8.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 196,936 shares of the company's stock after selling 18,103 shares during the period. Allianz Asset Management GmbH owned approximately 0.10% of Docusign worth $15,339,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. American Century Companies Inc. increased its stake in Docusign by 3.1% in the first quarter. American Century Companies Inc. now owns 5,477,758 shares of the company's stock valued at $445,890,000 after purchasing an additional 162,299 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Docusign by 18.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,028,505 shares of the company's stock worth $165,120,000 after acquiring an additional 318,698 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Docusign by 372.5% during the first quarter. Wellington Management Group LLP now owns 1,826,949 shares of the company's stock worth $148,714,000 after acquiring an additional 1,440,269 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Docusign by 6.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,431,901 shares of the company's stock worth $116,557,000 after acquiring an additional 89,948 shares in the last quarter. Finally, Pacer Advisors Inc. increased its position in shares of Docusign by 809.6% during the first quarter. Pacer Advisors Inc. now owns 1,167,290 shares of the company's stock worth $95,017,000 after acquiring an additional 1,038,962 shares in the last quarter. Institutional investors own 77.64% of the company's stock.

Docusign Trading Up 4.0%

Docusign stock opened at $70.68 on Tuesday. The company has a market cap of $14.21 billion, a P/E ratio of 53.14, a price-to-earnings-growth ratio of 3.38 and a beta of 1.02. Docusign Inc. has a 1-year low of $66.35 and a 1-year high of $107.86. The company has a fifty day simple moving average of $75.09 and a 200 day simple moving average of $77.92.

Docusign (NASDAQ:DOCU - Get Free Report) last announced its quarterly earnings results on Thursday, September 4th. The company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.08. The firm had revenue of $800.64 million during the quarter, compared to analysts' expectations of $780.35 million. Docusign had a net margin of 9.08% and a return on equity of 14.01%. The company's revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.97 earnings per share. Docusign has set its Q3 2026 guidance at EPS. FY 2026 guidance at EPS. On average, equities research analysts forecast that Docusign Inc. will post 1.17 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on DOCU. UBS Group set a $95.00 price objective on shares of Docusign in a research report on Friday, September 5th. Wells Fargo & Company increased their price objective on shares of Docusign from $80.00 to $85.00 and gave the stock an "equal weight" rating in a research report on Friday, September 5th. Morgan Stanley increased their price objective on shares of Docusign from $86.00 to $90.00 and gave the stock an "equal weight" rating in a research report on Monday, September 8th. Needham & Company LLC reissued a "hold" rating on shares of Docusign in a research report on Friday, September 5th. Finally, Piper Sandler increased their price objective on shares of Docusign from $85.00 to $90.00 and gave the stock a "neutral" rating in a research report on Friday, September 5th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and fifteen have issued a Hold rating to the company's stock. According to MarketBeat, Docusign has an average rating of "Hold" and a consensus target price of $94.14.

Insider Transactions at Docusign

In other Docusign news, insider James P. Shaughnessy sold 7,500 shares of the stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $71.19, for a total value of $533,925.00. Following the completion of the sale, the insider owned 55,442 shares in the company, valued at $3,946,915.98. This trade represents a 11.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Robert Chatwani sold 13,817 shares of the stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $83.10, for a total transaction of $1,148,192.70. Following the completion of the sale, the insider owned 71,162 shares of the company's stock, valued at approximately $5,913,562.20. This represents a 16.26% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 102,533 shares of company stock valued at $7,709,933. 1.66% of the stock is owned by company insiders.

About Docusign

DocuSign, Inc provides electronic signature solution in the United States and internationally. The company provides e-signature solution that enables sending and signing of agreements on various devices; Contract Lifecycle Management (CLM), which automates workflows across the entire agreement process; Document Generation streamlines the process of generating new, custom agreements; and Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.